While the role of TNF-α in the development of ALD has been well characterized [147], clinical investigations of the therapeutic efficacy of antibodies to TNF-α (e.g., infliximab) to treat patients with acute alcoholic hepatitis have generated variable results [139, 148]. This evidence concerns the gene TNF and alcoholic hepatitis.